Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Note 5 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

	As of December 31, 2015				Fair Value Measurements
	Carrying		Fair		As of December 31, 2015
	Amount		Value		Level 1		Level 2		Level 3
Assets:
Cash and cash equivalents:
Cash	$	7,534	$	7,534	$	7,534	$	—	$	—
Money market funds		776		776		776		—		—
	$	8,310	$	8,310	$	8,310	$	—	$	—
Marketable securities:
Money market funds	$	48	$	48	$	48	$	—	$	—
Mutual funds		58		58		58		—		—
U.S. Treasury securities		1,115		1,115		1,115		—		—
Government agency securities		131		131		131		—		—
	$	1,352	$	1,352	$	1,352	$	—	$	—
Liabilities:
Contingent consideration:
Asuragen	$	4,628	$	4,628	$	—	$	—	$	4,628
RedPath		13,921		13,921		—		—		13,921
	$	18,549	$	18,549	$	—	$	—	$	18,549

Fair Value Measurements as of

Carrying Amount as of

December 31, 2016

Level 1

Level 2

Level 3

Pancreas

Biobank

Total

			Fair Value Measurements as of
	Carrying Amount as of		December 31, 2015
	December 31, 2015		Level 1		Level 2		Level 3

Pancreas	$	2,625	$	-	$	-	$	2,625
Biobank		1,034		-		-		1,034
Total	$	3,659	$	-	$	-	$	3,659

Fair Value Measurements as of

Carrying Amount as of

December 31, 2015

Level 1

Level 2

Level 3

Goodwill